# BioAscent Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioascent-discovery

- Industry: Pharmaceuticals
- Headquarters: UK
- Website: www.bioascent.com
- Total disclosed funding: $3.6M
- Latest round: Series A (Jun 20, 2018)
- Investors on record: 1

## About

BioAscent Discovery Ltd is a UK-based company specializing in integrated drug discovery services, combining medicinal and synthetic chemistry, computational chemistry, and in vitro biosciences to support pharmaceutical and biotech clients in drug development.Founded in 2013 in the UK, BioAscent Discovery Ltd focuses on providing integrated drug discovery services. The company was established by Sylviane Boucharens, who has a history of founding other ventures. The latest funding round took place on June 20, 2018, raising GBP 2.75 million from Maven VCT, bringing the total amount raised to GBP 2.75 million and a current valuation of GBP 3.765 million.BioAscent specializes in integrated drug discovery services, offering a comprehensive suite of solutions that combines medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, drug metabolism and pharmacokinetics (DMPK), and compound management. Their primary objective is to streamline the drug discovery process for pharmaceutical and biotech clients, ensuring efficient development from initial discovery through to clinical candidates. The services are designed to address specific challenges in drug development, such as optimizing compound properties and managing large compound libraries. BioAscent serves a diverse client base, including pharmaceutical companies and biotechnology firms, across various geographical markets, including North America, Europe, and Asia-Pacific.In 2023, BioAscent reported revenue of GBP 12,529,322.70, with an EBITDA of GBP 624,304.90. The company generates revenue through a business-to-business (B2B) model, where clients engage in partnerships and collaborations for drug discovery projects. Transactions typically involve service agreements, where clients pay for specific services such as synthetic chemistry or DMPK studies based on their project requirements. The pricing structure is tailored to the unique needs of each client, accommodating both short-term projects and long-term collaborations.Following the funding raised on June 20, 2018, BioAscent aims to expand its services and reach new markets. The company is focusing on developing new products that align with their integrated drug discovery pathway. Specific geographic regions targeted for expansion include North America and Asia-Pacific, with plans to establish a stronger presence in these markets by 2024. The recent funding will support these initiatives, allowing BioAscent to enhance its capabilities and service offerings.

## Funding rounds

- Series A, Jun 20, 2018, $3.6M — Maven Capital Partners

## Investors

- Maven Capital Partners (https://capitalatlas.ai/funds/maven-capital-partners) — Series A